Funded in 2014 and resulting from the "Investments for the Future" French program, SATT Paris-Saclay is the Technology Transfer Acceleration Company of the Paris-Saclay Cluster.

A common player in both entities - Paris-Saclay University and Institut Polytechnique de Paris - the SATT has an investment capacity of 66 million euros over 10 years to finance and support the development of research work from the territory and the technology transfer to markets.

SATT Paris-Saclay supports the BB-100 lead product validation through two grants, POC'Up and Maturation, for a total of 616K€.

The Commissariat à l'énergie atomique et aux énergies alternatives (CEA) is a public scientific, technical and industrial research body (EPIC). A French major player in research, development and innovation, the CEA operates in four areas, defense and security, low-carbon energies (nuclear and renewable), technological research for industry, fundamental research in science of matter and life sciences.

CEA Paris-Saclay has awarded a worldwide exclusive licence to Blue Bees Therapeutics on i.Ther technology, and hosts the company's R&D laboratory

Bpifrance finances and supports companies - at each stage of their development - with loans, guarantees, aid for innovation and equity. In doing so, Bpifrance acts in support of public policies conducted by the Franch government and the Regions.

Bpifrance supports Blue Bees Therapeutics through grants, including BFTE and i.Lab, for a total of 465K€.

La French Tech Paris-Saclay is a non-profit organisation of innovative entrepreneurs representing the interests of the start-up community, scaleups and project developers based in the Paris-Saclay region, Yvelines, and Essonne on local, national and international levels.

La French Tech Paris-Saclay aims to unite this community to defend, promote and support start-ups that share common values, primarily focusing on producing disruptive innovations ("Deep Tech").